About

Conception.bio focuses on improving fertility treatments through advanced biotechnology. The company has developed a method to create viable egg cells from blood samples by transforming induced pluripotent stem cells (iPSCs) into mature egg cells. This process offers new possibilities for women to have children later in life, provides hope for couples facing infertility, and allows for genetic screening of embryos to avoid hereditary diseases. Unlike many competitors, Conception.bio directly serves individuals and couples, including same-sex male couples, through a business-to-consumer model. The goal is to lead in the fertility treatment market by providing effective solutions for those struggling with infertility.

Simplify's Take

What believers are saying

• Conception.bio's innovative technology could significantly extend the fertility window for women, offering a new lease on life for many.
• The potential to enable same-sex male couples to have biological children opens up a previously untapped market.
• Their cutting-edge research environment attracts top-tier scientific talent, fostering continuous innovation and maintaining a competitive edge.

What critics are saying

• The ethical and regulatory challenges surrounding the use of iPSCs for reproductive purposes could slow down adoption and market penetration.
• High R&D costs and the need for continuous innovation may strain financial resources, especially for a startup.

What makes Conception unique

• Conception.bio's unique process of generating viable egg cells from blood samples sets it apart from traditional fertility treatments.
• The use of induced pluripotent stem cells (iPSCs) for egg cell development is a groundbreaking technology that few competitors can match.
• Their focus on serving diverse clientele, including same-sex male couples, widens their market reach beyond conventional fertility clinics.

Help us improve and share your feedback! Did you find this helpful?

YesNo